Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality.
about
Role of Toll-Like Receptor Signaling in the Pathogenesis of Graft-versus-Host DiseasesThe role of pattern-recognition receptors in graft-versus-host disease and graft-versus-leukemia after allogeneic stem cell transplantationIndoleamine 2,3 dioxygenase in intestinal diseaseTLR/MyD88-mediated Innate Immunity in Intestinal Graft-versus-Host DiseaseAdvances in graft-versus-host disease biology and therapy.The role of dendritic cells in tissue-specific autoimmunity.Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new.Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantationA CD8 T cell/indoleamine 2,3-dioxygenase axis is required for mesenchymal stem cell suppression of human systemic lupus erythematosus.Innate immunity and transplantation tolerance: the potential role of TLRs/NLRs in GVHDInduction of indoleamine 2, 3-dioxygenase in human dendritic cells by a cholera toxin B subunit-proinsulin vaccine.Amino acid catabolism: a pivotal regulator of innate and adaptive immunity.Indoleamine 2,3-dioxygenase in human hematopoietic stem cell transplantation.Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantationImatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic-derived antigen-presenting cells.Allogeneic mesenchymal stem cells inhibited T follicular helper cell generation in rheumatoid arthritis.Engineering DNA nanoparticles as immunomodulatory reagents that activate regulatory T cells.Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity.Mouse mesenchymal stem cells suppress antigen-specific TH cell immunity independent of indoleamine 2,3-dioxygenase 1 (IDO1).The potential role of indoleamine 2,3 dioxygenase (IDO) as a predictive and therapeutic target for diabetes treatment: a mythical truth.Pathogenesis of acute graft-versus-host disease: from intestinal microbiota alterations to donor T cell activation.The gastrointestinal tract: properties and role in allogeneic hematopoietic stem cell transplantation.Indoleamine 2,3-dioxygenase and metabolites protect murine lung allografts and impair the calcium mobilization of T cells.IDO in human gut graft-versus-host disease.Indoleamine 2,3-dioxygenase and dendritic cell tolerogenicity.Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration.Homing in on acute graft vs. host disease: tissue-specific T regulatory and Th17 cells.Gene expression changes in HLA mismatched mixed lymphocyte cultures reveal genes associated with allorecognition.Indoleamine 2,3-dioxygenase: is it an immune suppressor?Hypoxia and Mucosal Inflammation.miR-153-3p, a new bio-target, is involved in the pathogenesis of acute graft-versus-host disease via inhibition of indoleamine- 2,3-dioxygenase.Non-hematopoietic cells contribute to protective tolerance to Aspergillus fumigatus via a TRIF pathway converging on IDO.Concise review: hitting the right spot with mesenchymal stromal cells.Danger signals activating innate immunity in graft-versus-host disease.Role of gut microbiota in graft-versus-host disease.Clinical perspectives for regulatory T cells in transplantation tolerance.Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance.New functions of protein kinase Gcn2 in yeast and mammals.Pathogenesis of graft-versus-host disease: innate immunity amplifying acute alloimmune responses.
P2860
Q26741220-0F1F9794-E913-4F94-BE0F-258081D1B996Q26824436-D9C6940E-5B41-488D-B4C5-B4B6C61DAB0BQ27025063-059BA422-3E59-4277-91AA-858EDB266DB7Q33835099-E67583FF-996C-4D13-B625-75FC4F12C3D0Q34031916-43874AD8-324A-4D5E-B9FB-59F14B38D5E2Q34422017-4AB266D3-E1B1-471E-859D-B99B5B6D4E59Q34754302-458BF86C-81ED-41D6-9947-B4CD5A1BDE32Q34973719-E9FAAC95-962B-4886-8DDA-170AB624E519Q35023185-0DDBF140-5CB0-4AB0-BBDA-A69349436780Q35084400-C25905B5-3E16-4CD3-B467-DAF1184DDA7FQ35122841-6BA04F4A-2C51-4779-A4B3-A44D09714732Q35261125-739F0F4E-9BC5-4655-9FC9-C012F779F19EQ35366857-543302D6-313F-43FA-804C-E37E05E5D12DQ35586614-D4942A12-55C8-4288-9B86-75A5D00BA907Q35753251-ADB4ACF1-BB9D-448C-A68C-DC1C1C3AB62BQ35909695-A903E430-DEF4-4319-99F2-04309A2FA95CQ35935923-85E5670B-00A7-48D7-98FD-84E397F0EB74Q35949475-A8955768-7A30-4E89-AA73-9A756B84600CQ36014986-92EE2624-C24C-495B-B761-1B9F6CC1B52AQ36041377-B7A73601-0BF9-47C7-9FAC-9672BF9B8D9DQ36117580-333C9ECC-129F-4FED-8014-3B8ADB154E50Q36130498-F7D9EC67-D9EA-444D-BB34-BF3F13C7AA67Q36264109-A9088163-0198-4A3E-8123-32F33E8F6354Q36369985-5F8490A6-0337-47B5-87C9-66409F9458DFQ36590698-5E2C0B7A-9F32-4175-91B7-E5188430E837Q36821053-C5833EAE-2F88-4E06-8254-0FBC5E45D9D5Q37186477-FBB82FCD-3C24-4988-BCB6-2113BEF127CFQ37223366-5F1C814A-C9A9-41B4-8E95-716ED1FEDDE4Q37320319-647B2698-2A42-4E03-A946-F0CD995EB4DBQ37362632-7036D151-125E-4CF4-A1EB-3EF5B5CCD5C2Q37550577-4F83DA34-EB23-4A93-965C-C89D9BA5DDB4Q37565461-A86E1F85-2381-4037-928A-43E6E06CC262Q37729196-A8C41380-9D32-4377-9648-357E014064D6Q37769501-11C9ADE1-4FF5-421D-B22D-00954A2F5978Q37875779-5504E8EA-C309-44FE-B479-2CD31F5F5D4BQ37887810-3FC81AA9-2C7B-4805-B290-38077734C4D6Q37912653-E618DFBB-2DCC-41E5-8795-5E4BBEE57676Q38047057-98367407-0334-4610-A766-B52183BF129BQ38057995-38B27D7A-2714-44A8-A31F-94F6A0A7490FQ38132090-E97C1196-F224-4401-B4FC-35AE10D37388
P2860
Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Inducing the tryptophan catabo ...... host disease (GVHD) lethality.
@en
Inducing the tryptophan catabo ...... host disease (GVHD) lethality.
@nl
type
label
Inducing the tryptophan catabo ...... host disease (GVHD) lethality.
@en
Inducing the tryptophan catabo ...... host disease (GVHD) lethality.
@nl
prefLabel
Inducing the tryptophan catabo ...... host disease (GVHD) lethality.
@en
Inducing the tryptophan catabo ...... host disease (GVHD) lethality.
@nl
P2093
P2860
P1433
P1476
Inducing the tryptophan catabo ...... host disease (GVHD) lethality.
@en
P2093
Andrew L Mellor
Christoph Bucher
David H Munn
Lisa K Jasperson
P2860
P304
P356
10.1182/BLOOD-2009-06-227587
P407
P577
2009-10-14T00:00:00Z